アレクシオンC5阻害剤による治療を受けたAQP4+ NMOSD患者登録

基本情報

NCT ID

NCT05966467

ステータス

募集中

試験のフェーズ

-

試験タイプ

観察

目標被験者数

122

治験依頼者名

Alexion Pharmaceuticals, Inc.

概要

Long-term, multicenter, multinational, observational, registry of patients with AQP4+ NMOSD that is designed to collect data on clinical outcomes and safety in patients prescribed Alexion C5 inhibitor therapies (C5IT). The registry will also collect data on patient reported outcomes (PROs), quality of life (QoL), and targeted AQP4+ NMOSD therapies used to provide evidence on the real-world impact of ALXN-C5IT on patients with AQP4+ NMOSD.

対象疾患

依頼者（Sponsor）